Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor

• US 20160271239A1
• Filed: 10/31/2014
• Published: 09/22/2016
• Est. Priority Date: 11/05/2013
• Status: Abandoned Application

• Current Assignee: Bavarian Nordic A/S
• Original Assignee: Bavarian Nordic A/S
• Inventors: FOY, SUSAN, MANDL, STEFANIE, ROUNTREE, RYAN, DELCAYRE, ALAIN
• Application Number:
  US15/034,496
• Publication Number:
  US 20160271239A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001106 Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
• CPC Class Codes: A61K 39/00117 Mucins, e.g. MUC-1
• CPC Class Codes: A61K 39/001182 Carcinoembryonic antigen [CEA]
• CPC Class Codes: A61K 39/001193 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
• CPC Class Codes: A61K 39/001194 Prostate specific antigen [PSA]
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 2710/24034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24043 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24071 Demonstrated in vivo effect
• CPC Class Codes: C12N 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/24143 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/24171 : Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present disclosure encompasses therapies, compositions, and methods for treatment of a human cancer patient using a recombinant poxvirus encoding a tumor-associated antigen in combination with one or more agonists or antagonists of immune checkpoint inhibitors.

Claims

1-56. -56. (canceled)

57. A therapy for the treatment of a human cancer patient, comprising:

(a) a recombinant orthopoxvirus comprising a nucleic acid encoding a polypeptide of at least one tumor antigen; and

(b) at least one of an anti-PD-1 antagonist, an anti-LAG-3 antagonist, or an anti-ICOS agonist;

wherein (a) and (b) are to be administered as a combination treatment.

67. A method for treating a human cancer patient comprising:

(a) administering to the patient a recombinant orthopoxvirus comprising a nucleic acid encoding a polypeptide of at least one tumor antigen; and

(b) administering to the patient at least one of an anti-PD-1 antagonist, an anti-LAG-3 antagonist, or an anti-ICOS agonist.

80. A method for treating a human cancer patient comprising:

(a) administering to the patient a priming dose of a recombinant orthopoxvirus comprising a nucleic acid encoding a polypeptide of at least one tumor antigen in combination with at least one of an anti-PD-1 antagonist, an anti-LAG-3 antagonist, or an anti-ICOS agonist; and

(b) administering to the patient one or more boosting doses of a recombinant avipoxvirus comprising a nucleic acid encoding a polypeptide of at least one tumor antigen in combination with at least one of an anti-PD-1 antagonist, an anti-LAG-3 antagonist, or an anti-ICOS agonist;